Jacobio Pharmaceuticals Group saw the highest growth of 299% in patent filings and 49% in grants in October in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 299% and grants by 49%. GlobalData’s DataBook provides a comprehensive analysis of Jacobio Pharmaceuticals Group’s patent filings and grants. Buy the databook here.
Jacobio Pharmaceuticals Group has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with four publications in Q4 2023
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings and grants with nearly 33% filings and 0% grants. The World Intellectual Property Organization(WIPO), Argentina(AR), European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Jacobio Pharmaceuticals Group is filings its patents. Among the top granted patent authorities, Jacobio Pharmaceuticals Group has 100% of its grants in United States(US)
Patents related to rare diseases lead Jacobio Pharmaceuticals Group's portfolio
Jacobio Pharmaceuticals Group has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q4 2023.
Leukemia related patents lead Jacobio Pharmaceuticals Group portfolio followed by lung cancer, and pancreatic cancer
Jacobio Pharmaceuticals Group has highest number of patents in leukemia followed by lung cancer, pancreatic cancer, colon cancer, and petrochemicals. For leukemia, nearly 11% of patents were filed and 10% of patents were granted in Q4 2023.
For comprehensive analysis of Jacobio Pharmaceuticals Group's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.